Inspire Medical Systems (INSP) to Announce Earnings on Monday

Inspire Medical Systems (NYSE:INSP) will likely be issuing its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $194.75 million for the quarter. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Monday, August 3, 2026 at 5:00 PM ET.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, May 4th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.38. The company had revenue of $204.58 million for the quarter, compared to analysts’ expectations of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. Inspire Medical Systems’s revenue was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.10 EPS. On average, analysts expect Inspire Medical Systems to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Inspire Medical Systems Trading Up 0.4%

NYSE:INSP opened at $49.38 on Monday. Inspire Medical Systems has a 12 month low of $38.91 and a 12 month high of $147.03. The firm’s 50 day moving average is $45.24 and its 200 day moving average is $57.09. The stock has a market capitalization of $1.42 billion, a PE ratio of 11.00, a price-to-earnings-growth ratio of 4.98 and a beta of 0.71.

Analysts Set New Price Targets

INSP has been the subject of a number of recent research reports. Evercore downgraded Inspire Medical Systems from an “outperform” rating to an “in-line” rating and set a $40.00 target price for the company. in a research report on Tuesday, June 23rd. Truist Financial increased their price target on Inspire Medical Systems from $50.00 to $54.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Zacks Research upgraded Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Freedom Capital raised Inspire Medical Systems to a “strong-buy” rating in a report on Tuesday, June 30th. Finally, Summit Redstone set a $39.00 price objective on Inspire Medical Systems in a research note on Friday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $74.83.

Institutional Investors Weigh In On Inspire Medical Systems

Several institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada boosted its holdings in shares of Inspire Medical Systems by 16.0% in the first quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock worth $5,220,000 after acquiring an additional 4,528 shares during the period. Integrated Wealth Concepts LLC bought a new stake in shares of Inspire Medical Systems during the 1st quarter valued at $524,000. Goldman Sachs Group Inc. raised its stake in shares of Inspire Medical Systems by 57.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock valued at $8,190,000 after purchasing an additional 18,857 shares during the period. Marshall Wace LLP lifted its holdings in Inspire Medical Systems by 3.8% during the 2nd quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock worth $2,064,000 after purchasing an additional 577 shares in the last quarter. Finally, Jump Financial LLC purchased a new stake in Inspire Medical Systems during the 2nd quarter worth about $931,000. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.